Watanabe, R.; Miura, N.; Kurata, M.; Kitazawa, R.; Kikugawa, T.; Saika, T. Unveiling the Genomic Landscape of Intraductal Carcinoma of the Prostate Using Spatial Gene Expression Analysis. Int. J. Mol. Sci.2024, 25, 4818.
Watanabe, R.; Miura, N.; Kurata, M.; Kitazawa, R.; Kikugawa, T.; Saika, T. Unveiling the Genomic Landscape of Intraductal Carcinoma of the Prostate Using Spatial Gene Expression Analysis. Int. J. Mol. Sci. 2024, 25, 4818.
Watanabe, R.; Miura, N.; Kurata, M.; Kitazawa, R.; Kikugawa, T.; Saika, T. Unveiling the Genomic Landscape of Intraductal Carcinoma of the Prostate Using Spatial Gene Expression Analysis. Int. J. Mol. Sci.2024, 25, 4818.
Watanabe, R.; Miura, N.; Kurata, M.; Kitazawa, R.; Kikugawa, T.; Saika, T. Unveiling the Genomic Landscape of Intraductal Carcinoma of the Prostate Using Spatial Gene Expression Analysis. Int. J. Mol. Sci. 2024, 25, 4818.
Abstract
Recently intraductal carcinoma of the prostate (IDCP) has attracted increasing interest owing to its unfavorable prognoses. To effectively identify the IDCP-specific gene expression profile, we took a novel approach of characterizing a typical IDCP case using spatial gene expression analysis. A formalin-fixed, paraffin-embedded sample was subjected to Visium CytAssist Spatial Gene Expression analysis. IDCP within invasive prostate cancer sites was recognized as a distinct cluster separate from other invasive cancer clusters. Highly expressed genes defining the IDCP cluster, such as MUC6, MYO16, NPY, and KLK12, reflected the aggressive nature of high-grade prostate cancer. IDCP sites also showed increased hypoxia markers HIF1A, BNIP3L, PDK1, and POGLUT1; decreased fibroblast markers COL1A2, DCN, and LUM; and decreased immune cell markers CCR5 and FCGR3A. Overall, these findings indicate that the hypoxic tumor microenvironment and reduced accessibility to immune cells, which reflect the pathological characteristics of IDCP, may influence the aggressiveness of high-grade prostate cancer.
Keywords
spatial gene expression analysis; intraductal carcinoma of the prostate (IDCP); hypoxic markers; immune cells; tumor microenvironment
Subject
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
